Viatris Inc. (VTRS) Stock
VTRS Key Statistics
About Viatris Inc.
Viatris Inc. operates as a global pharmaceutical and healthcare enterprise. Its business is structured across four primary geographic divisions: Developed Markets, Greater China, JANZ (Japan, Australia, New Zealand), and Emerging Markets. The company offers a comprehensive range of pharmaceutical products, encompassing branded prescription medications, generic and complex generic drugs, biosimilar treatments, and active pharmaceutical ingredients (APIs). These offerings target diverse therapeutic areas, addressing both noncommunicable and infectious diseases. Its biosimilars specifically focus on critical conditions in oncology, immunology, endocrinology, ophthalmology, and dermatology. Furthermore, Viatris's APIs are utilized across numerous drug categories, including antibacterials, central nervous system agents, antihistamines/antiasthmatics, cardiovascular, antivirals, antidiabetics, antifungals, and proton pump inhibitors. Beyond manufacturing medicines, Viatris supports patient well-being through additional services such as diagnostic clinics, educational seminars, and digital tools designed to assist with health management. Products are made available in various forms, including oral solids, injectable solutions, complex dosage formulations, and raw APIs. Viatris distributes these to a broad clientele globally, including retail pharmacies, wholesalers, government bodies, insurance providers, and institutional healthcare facilities. The distribution network involves pharmaceutical wholesalers, retail and institutional pharmacies, mail-order and e-commerce platforms, and specialty pharmacies. The company's extensive portfolio includes prominent brands like Lyrica, Lipitor, Creon, Influvac, Wixela Inhub, EpiPen auto-injector, Fraxiparine, Yupelri, Norvasc, Viagra, AMITIZA, Lipacreon, Effexor, Celebrex, and ARV. Its biosimilar franchises feature products such as Fulphila, Ogivri, Hulio, and SEMGLEE. Viatris Inc. also fosters innovation through strategic collaborations and licensing agreements with partners including Revance Therapeutics, Inc., Momenta Pharmaceuticals, Inc., Theravance Biopharma, Inc., Biocon Ltd., and Fujifilm Kyowa Kirin Biologics Co. Ltd. Founded in 1961, Viatris Inc. maintains its corporate headquarters in Canonsburg, Pennsylvania.
CEO: Scott Andrew Smith. Company website
VTRS — Frequently Asked Questions
What is the VTRS stock price today?
Viatris Inc. (VTRS) trades at $16.95, down 1.05% on the day, as of Sep 20, 2026 15:01 UTC.
What is Viatris Inc.'s market cap?
Viatris Inc. has a market capitalisation of $19.74B, calculated from the live VTRS share price and shares outstanding.
What is the P/E ratio of VTRS?
VTRS has no meaningful price-to-earnings ratio: Viatris Inc. lost $0.36 per share over the last twelve months, and a P/E is only defined on positive earnings.
How much revenue does Viatris Inc. make?
Viatris Inc. generated revenue of $14.74B over the trailing twelve months, which puts the stock at 1.34 times sales.
Does VTRS pay a dividend?
Yes. Viatris Inc. pays a dividend yielding 3.74% on the current share price.
What is the 52-week range for VTRS?
VTRS has traded between $9.43 and $18.39 over the past 52 weeks, and the last price is 7.8% below that high.
Is Viatris Inc. profitable?
No. Viatris Inc. is loss-making, with a net margin of -2.79% over the trailing twelve months.
What is the analyst price target for VTRS?
Wall Street analysts rate VTRS Hold, with an average price target of $20.50, 20.9% above the current price.
What sector is Viatris Inc. in?
Viatris Inc. is classified under the Healthcare sector and the Drug Manufacturers - Specialty & Generic industry, and is domiciled in US.
Who is the CEO of Viatris Inc.?
Scott Andrew Smith is the chief executive of Viatris Inc., which employs 30,000 people.
Where can I track VTRS in real time?
QFI Terminal shows VTRS with live charts, full financials, the options chain with gamma exposure, institutional ownership and analyst ratings on one screen. The free plan has no time limit and asks for no card.
See VTRS live in QFI Terminal
Interactive charts, full financials, options chain, gamma exposure, ownership and analyst ratings, all in one institutional-grade terminal.
Open VTRS in Terminal See plans